Could Scientists ‘Hack’ the Zika Virus to Kill Brain Cancer? – Livescience.com

The mosquito-spread Zika virus known for its links to brain damage in babies born to infected mothers has the potential to target and destroy brain cancer, scientists have found.

New research has revealed that the Zika virus breaks into brain cells by using a special molecular key, and scientists think the virus could be tweaked so that it infects only brain cancer cells, leaving healthy cells unharmed.

The aggressive brain cancer glioblastoma often defies standard cancer treatment because the disease transforms normal brain cells into stem cells. While typical neurons stop dividing after so many replications, stem cells can reproduce indefinitely and grow a whole new tumor from just a handful of cells. Patients typically survive less than 20 months after being diagnosed with glioblastoma; even if the cancer can be forced into remission, the tumors typically regrow and take the life of the patient within 12 months.

But where standard treatments fail, the Zika virus may offer a new strategy to wipe out the deadly disease, according to a pair of studies published Jan. 16 in the journals Cell Reports and Cell Stem Cell.

Related: The 9 Deadliest Viruses on Earth

"While we would likely need to modify the normal Zika virus to make it safer to treat brain tumors, we may also be able to take advantage of the mechanisms the virus uses to destroy cells to improve the way we treat glioblastoma," senior author Dr. Jeremy Rich, director of neuro-oncology and of the Brain Tumor Institute at UC San Diego Health, said in a statement. (Rich and his colleagues authored the Cell Stem Cell paper.)

When the Zika virus infects developing fetuses, the virus stunts brain development by targeting neural stem cells and stunting their proliferation. Rich and his co-authors wondered whether the virus' strategy could be co-opted to shrink brain tumors. In a 2017 study published in The Journal of Experimental Medicine, the team put their theory to the test and found that the Zika virus actually prefers to infect glioblastoma stem cells over normal brain cells at least in petri dishes and mouse models of the disease. The reason behind this preference remained a mystery, until now.

To learn how Zika breaches the membranes of cancer cells, the team scanned the virus' surface for integrins receptors that viruses often use to latch onto their victims' cells and slip inside. Having identified various integrins on the viral surface, the researchers then blocked each with a protein. Then, they unleashed the modified virus into a lab dish holding a mix of normal brain stem cells and cancerous ones. If a particular integrin helped Zika hack into brain cells, blocking the receptor should stop the infectious virus in its tracks.

Through trial-and-error, the team learned that an integrin called v5 serves as the key that lets Zika into brain cells.

"When we blocked other integrins, there was no difference," Rich said. "But with v5, blocking it with an antibody almost completely blocked the ability of the virus to infect brain cancer stem cells and normal brain stem cells."

Related: 5 Facts About Brain Cancer

According to the study, v5 consists of two halves: v and 5. The former half appears in abundance on brain stem cells, which may help to explain how the virus targets both healthy and cancerous brain stem cells. The latter half, however, mostly appears on cancer cells and renders tumors more aggressive, regarding how quickly they can spread.

For this reason, glioblastomas may be more vulnerable to Zika infection than normal brain stem cells. The team confirmed the idea by injecting Zika into human brain organoids tiny models of the human brain grown in a lab dish. In the mini-brains, the virus reliably infected cancer cells more often than healthy cells. But without an intact v5 receptor, the virus could not infect the cells at all.

The second study, published in Cell Reports, also confirmed that v5 grants Zika its cancer-crushing powers.

Using the CRISPR gene-editing technique, the researchers selectively deleted specific genes from glioblastoma stem cells and exposed each mutant tumor to the Zika virus. When they deleted the gene that contained instructions to build v5, Zika could no longer grab hold of the cancer cells. The discovery "made perfect sense" because v5 appears in such large quantities on neural stem cells, the virus' primary target, senior author Tariq Rana, professor and chief of the Division of Genetics in the Department of Pediatrics at UC San Diego School of Medicine and Moores Cancer Center, said in the statement.

Related: 7 Odd Things That Raise Your Risk of Cancer (and 1 That Doesn't)

With the knowledge that v5 may be a soft spot in aggressive glioblastomas, the researchers now aim to genetically modify the Zika virus to target the cancer while sparing healthy cells.

Other deadly viruses could also serve as weapons against brain cancer. In a study published in 2018 in The New England Journal of Medicine, researchers treated glioblastoma patients with a genetically modified poliovirus and found that more than 20% remained alive three years later, as compared with 4 percent of patients who received a standard treatment, Live Science reported at the time. As the field of virotherapy continues to grow, once-deadly diseases may prove to be powerful weapons in the fight against cancer.

Originally published on Live Science.

Here is the original post:
Could Scientists 'Hack' the Zika Virus to Kill Brain Cancer? - Livescience.com

Product Innovations and Technological Advancements to Boost the Growth of the Stem Cell Therapy Market in the Upcoming Years 2017 2025 Dagoretti…

In 2019, the market size of Stem Cell Therapy Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2019 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Stem Cell Therapy .

This report studies the global market size of Stem Cell Therapy , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

This study presents the Stem Cell Therapy Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Stem Cell Therapy history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global Stem Cell Therapy market, the following companies are covered:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Stem Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stem Cell Therapy , with price, sales, revenue and global market share of Stem Cell Therapy in 2017 and 2019.

Chapter 3, the Stem Cell Therapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stem Cell Therapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.

Chapter 12, Stem Cell Therapy market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.

Chapter 13, 14 and 15, to describe Stem Cell Therapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.

See more here:
Product Innovations and Technological Advancements to Boost the Growth of the Stem Cell Therapy Market in the Upcoming Years 2017 2025 Dagoretti...

Stem Cell Cartilage Regeneration Market Report 2019:2026 Industry Growth Forecasts by Manufacturers, Countries, Type and Application Dagoretti News…

The Stem Cell Cartilage Regeneration Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to drivers, opportunities, pricing details and latest trends in the industry.

The global Stem Cell Cartilage Regeneration Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Stem Cell Cartilage Regeneration Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.

Apply Here For Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/2448

Geographical segmentation of Stem Cell Cartilage Regeneration Market involves the regional outlook which further covers United States, China, Europe, Japan, Southeast Asia and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type and application.

Stem Cell Cartilage Regeneration Market: Competitive Landscape

Leading players operating in the global Stem Cell Cartilage Regeneration Market include: Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.

Scope of the Report

The key features of the Stem Cell Cartilage Regeneration Market report 2019-2026 are the organization, extensive amount of analysis and data from previous and current years as well as forecast data for the next five years. Most of the report is made up from tables, charts and figures that give our clients a clear picture of the Stem Cell Cartilage Regeneration Market. The structure of Stem Cell Cartilage Regeneration Market by identifying its various segments and sub-segments to help understanding the report.

Stem Cell Cartilage Regeneration Market Research Report gives current competitive analysis and also valuable insights to clients/industries, which will assist them to prepare a new strategy to expand or penetrate in a global Stem Cell Cartilage Regeneration Market.

As the report proceeds further, it covers the analysis of key market participants paired with development plans and policies, production techniques, price structure of the Stem Cell Cartilage Regeneration Market. The report also identifies the other essential elements such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit and consumption ratio.

Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2448

Important Stem Cell Cartilage Regeneration Market Data Available In This Report:

Do You Have Specific Requirement? Ask To Our Experts: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2448

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

For More Related Reports: http://bit.ly/Rajkumar123

Read the rest here:
Stem Cell Cartilage Regeneration Market Report 2019:2026 Industry Growth Forecasts by Manufacturers, Countries, Type and Application Dagoretti News...

Market opportunity and growth drivers of Cell Separation Technology Market till 2025 Dagoretti News – Dagoretti News

The comprehensive report issued byKD Market Insightsoffers a profound intelligence related to the various aspects that are likely to impact the demand, revenue generation, and sales of theCell Separation Technologyin the near future. In addition, the report singles out the different parameters that have high potential to influence the overall dynamics of theCell Separation Technology Marketduring the forecast period 2019-2025.

As per the findings of the market study, theCell Separation Technology Marketis poised to surpass the value of USDXXBillion by the end of 2025, thriving at a CAGR ofXX% over the assessment period 2019-2025. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio and the distribution networks of the Cell Separation Technology in different regions, import-export trends and more to provide readers an adequate understanding of the global market scenario.

Get Sample Report:https://www.kdmarketinsights.com/sample/5330

The Presented Study Addresses the Following Queries Related to The Cell Separation Technology Market:

What was the worldwide market valuation in 2019? What will be the market growth during the forecast period i.e. 2020-2025?

Which region would have the most promising demand for the product in the coming years?

What are the crucial factors driving the growth of the market?

Which sub-market will make the most substantial contribution to the market?

What are the promising market opportunities for existing and entry-level players?

What are various long-term and short-term strategies implemented by leading market players?

This market research report dives deep into understanding the business strategies adopted by leading market players in the global Cell Separation Technology market. Further, the SWOT analysis for leading market players is enclosed in the report along with the financials, pricing analysis, recent activity and product overview of each company.

The extensive study on the Cell Separation Technology market pinpoints the different factors that are likely to influence the prospects of the Cell Separation Technology market in each region.

Pivotal Information Added in the report:

The scenario of the global Cell Separation Technology market in different regions

Current market trends influencing the growth of the Cell Separation Technology market

Factors expected to limit the growth of the global Cell Separation Technology market

Micro and macro-economic factors shaping the growth of the market in different regions

Key strategies adopted by players to gain a competitive edge in the Cell Separation Technology market

Get Complete Research Report with TOC @:https://www.kdmarketinsights.com/product/5330/cell-separation-technology-market

Key Players Profiling and Market Segmentation Analysis Offered:

Based on Technology Type: Immunomagnetic Cell Separation Fluorescence-activated Cell Sorting (FACS) Density Gradient Centrifugation Immunodensity Cell Separation Microfluidic Cell Separation Others

Based on Application: Stem Cell Research Immunology Neuroscience Cancer Research Others

Based on End-user: Biotechnology & Pharmaceutical Companies Hospitals & Diagnostic Laboratories Academic & Research Institutes Others

The companies studied in the report are:

Akadeum Life Sciences STEMCELL Technologies, Inc. BD Bio-Rad Laboratories, Inc Miltenyi Biotech 10X Genomics Thermo Fisher Scientific, Inc. Zeiss GE Healthcare Life Sciences PerkinElmer, Inc. QIAGEN Other Major & Niche Key Players

Visit link:
Market opportunity and growth drivers of Cell Separation Technology Market till 2025 Dagoretti News - Dagoretti News

Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines – Business Wire

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology and Pharmaceuticals, Inc. (President and CEO: Jiwu Wang, Ph.D., Allele), a San Diego-based private company, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas), through its Massachusetts-based subsidiary Astellas Institute for Regenerative Medicine (AIRM), entered into a licensing agreement to expand Astellas access to Alleles induced pluripotent stem cell (iPSC) technologies for various cell therapy programs.

Astellas, one of the largest pharmaceutical companies in Japan and already a leader in the development of cell-based therapeutics, has further dedicated to development of the field through its commitment to state-of-the-art iPS cell generation, modification, and manufacturing. iPSC lines can differentiate into all somatic tissue types, enabling a wide variety of therapeutic applications. The field of iPSC-derived cells has seen dramatic growth in clinical trials recently--the majority of the ~12 clinical trials around the world were initiated within the last 18 months and many more are upcoming.

Allele has been developing its core strength in reprogramming somatic cells into iPSCs with granted patents and the first commercial cGMP system it developed over the past 10 years. Allele also engages in more than a dozen different human tissue derivation activities through its own R&D efforts for internal programs and partnerships. To realize the unparalleled potential of iPSC, Alleles researchers and cGMP team are committed to setting up and validating cell assays for product quality control, genome analysis pipelines, closed-system automation for reprogramming, and machine learning in iPSC-related fields.

Under the terms of the new license agreement, Astellas will pay Allele upfront and milestones, product-based royalties, and potentially manufacture fees.

About AlleleAllele Biotechnology and Pharmaceuticals was founded in 1999. In 2015, the company completed an 18,000 square foot state-of-the-art facility in San Diego for the production of GMP-grade human iPSC lines. The facility also supports the production of tissue-specific cells differentiated from these iPSCs, including pancreatic beta cells, neural progenitor cells, and cardiomyocytes.

View original post here:
Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Business Wire

SVHI PRP Therapy Announces New Website Focused on PRP for Hair Loss in the San Francisco Bay Area – Benzinga

FOSTER CITY, Calif., Jan. 17, 2020 /PRNewswire-PRWeb/ --SHVI PRP Therapy, the leader in innovative hair loss treatments based on PRP (Platelet Rich Plasma) at https://svhi-prp.com/, is proud to announce a new website. The new website is a "microsite," focused specifically at the use of PRP to mitigate hair loss. Many Bay Area consumers are open to cutting edge technologies, and PRP is one option in their hair loss journey.

"PRP therapy for hair loss is an innovative option for many Bay Area patients," explained Miguel Canales, surgeon and founder of SVHI PRP therapy. "Even more important, a patient who seeks out a consultation with me on hair loss will be able to review the entire range of options from PRP therapy to hair loss to hair transplantation. I will work with each patient to create the best treatment program for their hair loss needs."

Persons who would like to learn more about the company can visit the new website. In particular, they can focus on the page specific to PRP therapy can visit https://svhi-prp.com/prp-therapy/. Another option is to read the FAQ (Frequently Asked Questions) document at https://svhi-prp.com/faq/. That document explains as follows. Hair thinning in women, which affects nearly 40 million American women, is mainly due to heredity and can start any time after puberty. However, we also know that female pattern hair loss can be strongly influenced by age, nutrition, stress, surgery, medications, illness, social/lifestyle factors, hair care and more. As hair follicles weaken and stop producing hair, hair loss occurs. Remarkably, PRP for hair loss can impact the hair itself, often resulting in hair rejuvenation.

PRP or Platelet Rich Plasma for hair loss is an in-office, non-surgical, treatment derived from the patient's own blood that can be performed in about an hour. After the area of concern is identified, evaluated and measured, standardized medical photos are taken in the photo suite. Special gentle and sterile techniques and equipment are used to separate and concentrate the platelets and plasma from a small sample of peripheral blood. PRP contains growth factors and cytokines that have been shown to be responsible for stimulating and enhancing hair follicle function. The scalp is prepared with antiseptic solution and anesthetic (a "ring block," not simply local anesthetic gel) is used to completely numb the scalp. Small injections of the PRP deliver the powerful platelet-derived growth factors into the skin at the level of the weak follicles. Electronic, mechanical microneedling is performed.

ABOUT SVHI PRP THERAPY

SVHI PRP Therapy is a Bay Area company based in Foster City, California, that offers PRP for hair loss to clients from San Francisco to San Mateo, Palo Alto to Redwood City, Redwood City to Burlingame and beyond. Clients who are suffering from hair loss and are seeking innovative therapy come to SVHI PRP Therapy to explore their options, including PRP therapy for hair loss. The company offers a no obligation consultation on hair loss with Dr. Miguel Canales, a recognized specialist in the hair loss industry including hair transplantation.

SOURCE SVHI PRP Therapy

Here is the original post:
SVHI PRP Therapy Announces New Website Focused on PRP for Hair Loss in the San Francisco Bay Area - Benzinga

Learning to be relentless – The Daily Republic

Thats something 13-year-old Floyd Korzan learned the hard way when his father, Matt, was diagnosed with acute myeloid leukemia, a highly-deadly form of blood cancer, after he fell ill on a family hiking trip in the Black Hills in 2012.

Matts fight against the disease has since taken the Mitchell family on a journey of frightening lows and celebratory highs and led Floyd to start Relentless Pledge, a non-profit organization that encourages patients to be as relentless as his father as they fight to achieve the goal of overcoming cancer.

We basically have two goals. The first one is to inspire others to overcome obstacles and dream their dreams. And the second part of the goal is to give a Relentless wristband to every cancer patient in Mitchell, our hometown, and eventually, if we get big enough, South Dakota and the United States, Floyd said in an interview with the Daily Republic.

Its a goal borne out of Floyds experience when he sat with his father at the Mayo Clinic in Rochester, Minnesota as he underwent treatments for the disease. Matt beat the leukemia once, but it later returned, a bad sign when associated with this particular kind of cancer. It went into remission again but returned again in 2017, and doctors were not hopeful.

With few options remaining, Matt agreed to a stem cell donation treatment that would use cells provided by his sister, Margaret, who happened to be a 100 percent match, injected into his system following an intense round of chemotherapy. The treatment was difficult, but after 8 million donor cells were circulated through his system, the doctors began to see good results.

Little by little, I came back, Matt said. After 30 days, they did a bone marrow biopsy that showed no evidence of leukemia whatsoever. They did another one at the end of the year, still no evidence of leukemia. They did one at the two-year mark, still no evidence of leukemia.

Visitors to relentlesspledge.org can nominate individuals to receive Relentless wristbands, which remind people to stay the course when attempting to achieve their goals. (Erik Kaufman / Republic)

Floyd recounted the scary days of his dads fight in an essay posted on his website relentlesspledge.org. He asked his father at the time how he could be as strong as he was even as he suffered from the disease and the side effects of his treatment. Matts response was that there may be times in life when the only person left who believes in you is you, and in those times, you must be relentless in order to make it through.

Floyd had found his own inspiration in his fathers fight, and he wanted to spread that inspiration to others who were suffering. Normally a private person, Matt agreed to share his story with the public and helped his son form Relentless Pledge, which encourages people to live life to the limit, to dare, to dream, and be relentless in overcoming challenges.

Visitors to the website can take the pledge, as well as nominate individuals to receive one of the symbols of the organization: a wristband bearing the word Relentless. Visitors can also order wristbands for themselves, family members, friends as well as cancer patients.

The goal is to spread the message of hope to every cancer patient in America, Floyd said. He has shipped orders of wristbands to 26 states around the country and three continents already, and the pair plan to pass out the wristbands to people in the leukemia ward at the Mayo Clinic, where Matt returns periodically for continued treatments. More wristbands will be given out at the Avera Cancer Center in Mitchell.

In total, they estimate theyve given out about 400 of them so far. And the campaign is officially less than two weeks old.

It seemed to strike a chord with people, Matt said.

As the young program grows, Floyd said the organization could expand to include more than just cancer patients in its message. There are others who are trying to accomplish goals, as well, such as public servants or community-minded individuals.

Its not all about cancer. Now were looking at giving them out to local heroes," Floyd said. "So far, weve given them to local firefighters and the librarians at the Mitchell Public Library, and were thinking about the police department."

Floyd hopes Relentless Pledge continues to grow. He is eyeing expanding the Relentless line to include t-shirts that would promote the Relentless Pledge, but for now he is concentrating on fulfilling orders for the wristbands and getting them in the hands of people who need inspiration.

I have big dreams in the future where this organization could expand to have a full line of accessories, Floyd said. Relentless gear.

Matt said he is recovering a little more each day, and hes grateful. Hes been able to throw the ball around in the yard with Floyd again, and he is working to become stronger as he continues his recovery. He said hes grateful for the love and support of Floyd as well as his wife Bam and other children Alexis, Cassidy, Hailey and Jackson. Hes thankful for doctors like Kebede Begna and Lucio Margallo, both of whom Matt described as relentless in helping him fight for his health.

And hes happy to help Floyd spread the message of hope through Relentless Pledge, he said.

I think its great. I think its a noble project, and I think its good for Floyd. Of all the ways a teenager can spend their time, this is pretty solid, Matt said.

Floyd said he plans to continue his work with the organization well into the future. He has a little over four years left before he leaves for college, and with that time he plans to do everything he can to remind those who are struggling to remain relentless.

One Relentless wristband at a time.

The next step is spreading the word, Floyd said.

More:
Learning to be relentless - The Daily Republic

Here’s Why Stemline Therapeutics Dropped Today – Motley Fool

What happened

Shares of Stemline Therapeutics (NASDAQ:STML) were down 34% at 11:42 a.m. EST after the company released disappointing preliminary fourth-quarter results.

The biotech estimates that it sold $11.8 million worth of Elzonris, a drug that treats blastic plasmacytoid dendritic cell neoplasm (BPDCN), a type of blood cancer. That's lower than the $13.1 million Stemline Therapeutics sold in the third quarter -- when, as the company noted, the number of new patients on the drug increased by over 20% quarter over quarter.

Management didn't give much color on the reason for the quarter-over-quarter decline in the press release, but the company has noted in the past that BPDCN is often misdiagnosed, and it was working with doctors to increase the speed and accuracy of diagnoses. Management will likely update investors on the progress and reason for the sales slowdown during the company's presentation at the J.P. Morgan Healthcare Conference on Wednesday.

Image source: Getty Images.

The slowdown in launch trajectory is certainly disappointing, but Stemline Therapeutics has plenty of opportunities to turn things around. Elzonris is under review by EU regulators, setting up a likely approval this year.

Further down the line, there's potential to expand Elzonris into other blood cancers; the company is currently testing the drug in three different blood cancers -- chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia -- with clinical trial data in all three expected this year. There's also potential to move Elzonris into the maintenance setting for patients treating their BPDCN through a stem cell transplant; initial data in that setting is expected this quarter.

Continued here:
Here's Why Stemline Therapeutics Dropped Today - Motley Fool

Medics key to spotting signs of child abuse, Abu Dhabi conference hears – The National

The crucial need to spot the telltale signs of child abuse was high on the agenda as a global medical conference got under way in Abu Dhabi on Thursday.

Experts said doctors and nurses were well placed to uncover any early child abuse indicators, but must be clear in their diagnosis as bruising is common and can often indicate serious illnesses such as leukaemia.

The vital topic was put under the microscope during the opening sessions of the 14th Seha International Paediatric Conference at the Rosewood hotel on Al Maryah Island.

Doctors and other healthcare professionals will assess the latest developments in child healthcare during the three-day conference.

It can be the most amazing family in the world, but abuse in the home can be happening and doctors can quickly determine that with a proper physical assessment, said Dr Leslie Lehman, clinical director of paediatric stem cell transplants at Boston Childrens Hospital in the US.

A detailed history and physical exam of a child can determine the cause of bruising and rule out abuse.

Most bruises in childhood are result of minor environmental interactions.

If doctors are still unsure of the cause of bruising, a paediatric haematologist should be consulted.

Researchers also discussed breakthroughs in how to spot early signs of sepsis, paediatric hypertension, and bone and joint infections.

Delegates from some of the leading international care facilities attended the event to share their most recent findings and research.

They included experts from the Childrens Hospital in Philadelphia, the Cincinnati Childrens Hospital, Boston Childrens Hospital, National Childrens Hospital in Washington and Londons Great Ormond Street Hospital.

Abu Dhabi Health Services Company, the UAEs largest healthcare network, is hosting the 14th edition of a conference that has become one of the most prominent in the field, providing significant advantages to professionals who serve children in the UAE and the wider region.

Sehas priority is to offer children with services and treatment methods that match, if not exceed, the highest international standards, said Dr Elsadeg Mohamed Sharif, a consultant paediatrician at Al Ain Hospital.

It is dedicated to utilising the available technology and expertise worldwide to deliver on that promise.

Updated: January 16, 2020 03:05 PM

Read more:
Medics key to spotting signs of child abuse, Abu Dhabi conference hears - The National

Smart Group & A4M Concluded their First India Conference 2020 – NewsPatrolling

Smart Group & American Academy of Anti-Aging Medicine have successfully concluded their first conference featuring esteemed speakers, experts, clinicians, and researchers in the field of Integrative and Functional Medicine.

New Delhi 18 January 2020 On Saturday, January 18th, 2020, the Smart Group in partnership with A4M together held their 1st India Conference at the Hyatt Regency, New Delhi. The two-day conference featured esteemed speakers, celebrated doctors and learned professionals in the field of preventive, integrative and traditional medicine from India and across the globe.

Addressed by some of the worlds leading faculty in preventive healthcare, this groundbreaking event was attended by more than 300 doctors and featured the most cutting edge and futurists innovations in healthcare.The guest speakers at the conference were globally renowned scholars who have been leading integrative medicine globally and key leaders of the$4trillion global wellness industry which is due to swell to$30trillion.

The audience had a chance to listen to globally renowned speakers like Dr Andrew Heyman (MD, MHSA); Dr Pamela Smith (MD, MPH, MS); Dr Daniyar Jumaniyazov (MD, PhD); Dr Graham Simpson (MD); Dr Brian Delaney (PHD) and Indian health leaders like Deepak A V Chaturvedi (MD), endocrinologist from Mumbai; Alok Sharma, President, Stem Cell Society India; Dr BS Rajput Vice President , Stem Cell Society India ; functional medicine experts like celebrity nutritionist, Dr Anjali Hooda amongst others.

A series of sessions as conducted by renowned industry experts, featured new age topics including intermittent fasting, regenerative medicine, autoimmunity, biochemical detox, and sub-fertile male amongst others, all of which have taken urban India by storm and are being increasingly endorsed by celebrities from Bollywood, sports and even politics. A key feature of the conference was the scientifically curated exhibition featuring nutraceutical providers, companies in cellular regeneration & gene testing, healthcare equipments enabled by artificial intelligence. Healthcare stalwarts like Dabur and Apollo showcased their futuristic vision for healthcare in India

Keeping with the futuristic theme of the conference, Dr M (BK Modi) Founder-Chairman, Smart Group, addressed the audience via a video conference. Detailing his own experience with stem cells, he said, I am very glad that doctors in India are taking a keen interest in preventive health. Cellular therapy has personally given me a renewed zeal and has enabled me to pursue my passion despite my age. I wish more people discover the benefits of preventive health, and can lead happy & healthy lives, beyond 100.

The thought was echoed by Ms Preeti Malhotra (Chairman, Smart Bharat and President Organising committee, Smart A4M India conference, Medicine has taken an exponential leap this century. Preventive health has had a profound effect on human longevity, awareness, mental wellbeing. There are researches claiming that children born in the coming years may live for upto a 1000 years, this has a profound effect on social relations, economies and the future of a nation. I am very happy that we were a able to bring A4M into India to initiate this conversation, much needed in a country like ours.

Given the resounding success of Smart Group & A4Ms 1st India Conferences Day 1, its hoped that the Day 2 shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

Read more from the original source:
Smart Group & A4M Concluded their First India Conference 2020 - NewsPatrolling